- Report
- May 2024
- 128 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- October 2024
- 184 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 185 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- July 2024
- 145 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- March 2025
- 196 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- January 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- September 2024
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 327 Pages
Global
From €2662EUR$2,800USD£2,236GBP
€3803EUR$4,000USD£3,195GBP
- Report
- January 2025
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- May 2022
- 228 Pages
Global
From €2495EUR$2,625USD£2,096GBP
€4991EUR$5,250USD£4,193GBP
- Report
- April 2022
- 307 Pages
Global
From €5276EUR$5,550USD£4,432GBP
- Report
- February 2023
- 144 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- August 2024
- 80 Pages
Japan
From €3327EUR$3,500USD£2,795GBP
- Report
- August 2023
- 117 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- May 2023
- 118 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- August 2022
- 138 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- June 2021
- 102 Pages
Global
€20914EUR$22,000USD£17,570GBP
- Report
- April 2023
- 111 Pages
Global
From €4516EUR$4,750USD£3,794GBP

Von Willebrand Disease (VWD) is a rare inherited bleeding disorder caused by a deficiency or defect in the von Willebrand factor (VWF), a protein that helps the blood to clot. It is the most common inherited bleeding disorder, affecting both males and females. Symptoms of VWD can range from mild to severe, and include prolonged bleeding from cuts, nosebleeds, and heavy menstrual bleeding. Treatment for VWD typically involves the use of desmopressin, a synthetic form of the hormone vasopressin, and/or replacement therapy with VWF concentrates.
The VWD market is a subset of the larger hematology market, which includes treatments for a variety of blood-related disorders. The VWD market is expected to grow due to increasing awareness of the disorder, as well as the development of new treatments.
Companies in the VWD market include Shire, CSL Behring, Octapharma, Grifols, and Kedrion. Show Less Read more